Atorvastatin | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Atorvastatin
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

Egis Atorvastatin - Dapagliflozin

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Atorvastatin

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

147 API Suppliers, 65 USDMF, 43 CEP/COS, 20 JDMF, 30 EU WC, 86 KDMF, 27 NDC API, 76 Listed Suppliers, $ API Reference Price

147 API Suppliers
65 USDMF
43 CEP/COS
20 JDMF
30 EU WC
86 KDMF
27 NDC API
76 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

1556 FDF Dossiers, 187 FDA Orange Book, 790 Europe, 104 Canada, 83 Australia, 65 South Africa, 327 Listed Dossiers

1556 FDF Dossiers
187 FDA Orange Book
790 Europe
104 Canada
83 Australia
65 South Africa
327 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 40MG BASE, TABLET;ORAL - EQ 80MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 10MG BASE
TABLET;ORAL - EQ 20MG BASE
TABLET;ORAL - EQ 40MG BASE
TABLET;ORAL - EQ 80MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 5 Evonik, 3 Rochem International Inc, 23 SPI Pharma, 2 Seqens, 14 DKSH, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 2 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 7 Gangwal Healthcare, 2 Kewpie Corporation, 5 Nanjing Well Pharmaceutical, 3 Pfanstiehl, 1 Pramukh Pharmachem, 1 ACG Worldwide, 7 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 18 BASF, 1 BioSpectra, 12 Corel Pharma Chem, 7 DFE Pharma, 1 Finar, 10 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 8 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

91 Fillers, Diluents & Binders, 59 Coating Systems & Additives, 38 Direct Compression, 36 Disintegrants & Superdisintegrants, 30 Thickeners and Stabilizers, 30 Controlled & Modified Release, 27 Taste Masking, 24 Granulation, 24 Solubilizers, 22 Parenteral, 22 Lubricants & Glidants, 21 Film Formers & Plasticizers, 20 Chewable & Orodispersible Aids, 18 Topical, 16 Co-Processed Excipients, 11 Emulsifying Agents, 9 Rheology Modifiers, 8 API Stability Enhancers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 3 Surfactant & Foaming Agents

91 Fillers, Diluents & Binders
59 Coating Systems & Additives
38 Direct Compression
36 Disintegrants & Superdisintegrants
30 Thickeners and Stabilizers
30 Controlled & Modified Release
27 Taste Masking
24 Granulation
24 Solubilizers
22 Parenteral
22 Lubricants & Glidants
21 Film Formers & Plasticizers
20 Chewable & Orodispersible Aids
18 Topical
16 Co-Processed Excipients
11 Emulsifying Agents
9 Rheology Modifiers
8 API Stability Enhancers
5 Empty Capsules
4 Vegetarian Capsules
4 Coloring Agents
3 Surfactant & Foaming Agents

DIGITAL CONTENT

153 NEWS #PharmaBuzz

153 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 662 Finished Drug Prices, 20 Annual Reports

2 US Medicaid Prescriptions
662 Finished Drug Prices
20 Annual Reports

MARKET PLACE

56 APIs, 21 FDF Dossiers, 1 Intermediates

56 APIs
21 FDF Dossiers
1 Intermediates

PATENTS & EXCLUSIVITIES

5 US Patents, 72 Health Canada Patents

5 US Patents
72 Health Canada Patents

REF. STANDARDS & IMPURITIES

6 EDQM, 7 USP, 4 JP, 20 Others

6 EDQM
7 USP
4 JP
20 Others

ANALYTICAL

5 BioAnalytical Methods

5 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 215 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

5 All

01 5CMP DEV LLC

filter Patent Number Reset all filters

5 All

01 111369567

02 211654106

03 111925704

04 112168069

filter API Patent Reset all filters

5 All

01 5Blank

filter FDF Patent Reset all filters

5 All

01 5Y

filter Expiration Date Reset all filters

5 All

01 52037-06-07

Product Main Page

01

CMP DEV LLC

ATORVASTATIN CALCIUM

BioAsia

Not Confirmed

CMP DEV LLC

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11654106

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3612

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

CMP DEV LLC

ATORVASTATIN CALCIUM

BioAsia

Not Confirmed

CMP DEV LLC

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11654106

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3613

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

CMP DEV LLC

ATORVASTATIN CALCIUM

BioAsia

Not Confirmed

CMP DEV LLC

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11925704

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3853

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

CMP DEV LLC

ATORVASTATIN CALCIUM

BioAsia

Not Confirmed

CMP DEV LLC

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 12168069

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

CMP DEV LLC

ATORVASTATIN CALCIUM

BioAsia

Not Confirmed

CMP DEV LLC

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11369567

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!